approach to tachyarrhythmias
Unstable → synchronised cardioversion, whatever the rhythm. Stable → 12-lead ECG during tachycardia, then sort by QRS width and regularity. Regular narrow → vagal manoeuvre → adenosine 6 → 12 → 18 mg (terminates AVNRT/AVRT; unmasks flutter/AT). Wide and uncertain → treat as VT; never verapamil/diltiazem. Irregular, very fast, bizarre wide complexes → pre-excited AF → procainamide or ibutilide, no AV-nodal blockers.
- Pre-excited AF — AV-nodal blockers (adenosine, verapamil, diltiazem, beta-blocker, digoxin, IV amiodarone) can precipitate VF
- VT mislabelled as SVT with aberrancy — wide complex + structural heart disease = VT until proven otherwise
- Sinus tachycardia from sepsis, bleeding, PE, hypoxia — treat the cause, not the rate
Irregular, very fast, varying wide QRS. Unstable → synchronised cardioversion.
- procainamide or ibutilide IV
- DCCV if it persists; refer to ablate the pathway
- AV-nodal blockers — adenosine, verapamil, diltiazem, beta-blocker, digoxin
- IV amiodarone — enhances pathway conduction → VF
mechanism → management
- AV node in the circuit (AVNRT, orthodromic AVRT) → anything that transiently blocks the node (vagal, adenosine, CCB, BB) terminates it
- AV node as bystander (flutter, atrial tachycardia, AF) → nodal block only slows the ventricle and unmasks the atrial rhythm — diagnostic, not curative
- Accessory pathway has no decremental conduction → AF conducts down it at >250/min; blocking the node shifts more conduction to the pathway → VF
- CCB in VT → vasodilation + negative inotropy on a ventricle already failing → collapse
- Adenosine acts via A1 receptors on the AV node (AH interval), half-life seconds → rapid proximal bolus + flush; can trigger AF (more often with AVRT) and accelerate pre-excited rhythms
algorithm
graph TD
A[Tachycardia] --> B{Unstable?<br/>hypotension, ischaemia, AMS, HF}
B -->|yes| C[Synchronised DC cardioversion]
B -->|no| D[12-lead ECG during tachycardia]
D --> E{QRS ≥120 ms?}
E -->|no, regular| F[Vagal manoeuvre → adenosine 6–12–18 mg<br/>then IV verapamil/diltiazem or beta-blocker]
E -->|no, irregular| G[AF, flutter with variable block, multifocal AT<br/>→ rate control]
E -->|yes, regular| H[Presume VT<br/>adenosine only if no pre-excitation on resting ECG<br/>DCCV or IV procainamide; amiodarone second line]
E -->|yes, irregular| I{Very fast, varying bizarre QRS?}
I -->|yes| J[Pre-excited AF<br/>procainamide or ibutilide; DCCV<br/>NO AV-nodal blockers]
I -->|no| K[AF with aberrancy, or polymorphic VT<br/>check QT]
narrow complex tachycardia (QRS <120 ms)
| Rhythm | Regular? | Clues |
|---|---|---|
| sinus tachycardia | yes | gradual onset/offset, normal P before each QRS; look for the driver |
| AVNRT | yes | abrupt onset; P buried in QRS or pseudo-r′ in V1 |
| orthodromic AVRT | yes | abrupt onset; retrograde P in ST segment; pre-excitation in sinus rhythm (WPW) or concealed pathway |
| atrial flutter | yes (fixed block) | rate ~150 with 2:1; sawtooth inferior leads, unmasked by adenosine |
| focal AT | yes or variable | abnormal P morphology, warm-up |
| AF / MAT | no | no organised P (AF); ≥3 P morphologies (MAT, lung disease) |
acute treatment (stable)
- Vagal manoeuvres supine with legs raised — modified Valsalva (strain semi-recumbent — blow into a 10 mL syringe hard enough to move the plunger — then lie flat with passive leg raise) ~43% vs 17% conversion. Carotid massage: unilateral, ≤5 s, not with bruit or prior stroke/TIA
- Adenosine 6 mg rapid IV bolus via antecubital vein + immediate flush → 12 mg → consider 18 mg; repeat safe within 1 min. Warn of flushing, chest pain, dyspnoea. Caution with known sinus node disease; severe asthma → verapamil preferred
- Verapamil 0.075–0.15 mg/kg (5–10 mg) over 2 min or diltiazem 0.25 mg/kg (~20 mg) over 2 min — avoid if hypotension, LVEF <40%, suspected VT or pre-excited AF
- Beta-blocker (esmolol, metoprolol) — avoid in decompensated HF
- Synchronised DCCV if drugs fail or are contraindicated, even when stable (I)
| Response to adenosine | Meaning |
|---|---|
| terminates | AVNRT or AVRT (node in circuit) |
| transient AV block revealing flutter waves / P waves | flutter or atrial tachycardia (node is bystander) |
| gradual slowing, then re-acceleration | sinus tachycardia or automatic AT |
| no effect | inadequate dose/delivery, or high septal VT |
long-term
- Recurrent symptomatic AVNRT or AVRT → catheter ablation first-line (I; high cure rate, low complication rate)
- Drugs if ablation declined: beta-blocker, diltiazem/verapamil (not with manifest pre-excitation), flecainide/propafenone if no structural heart disease → antiarrhythmics
- Typical flutter: anticoagulate as AF; CTI ablation for recurrent symptomatic flutter (I). Cardioversion: low-energy DCCV (≤100 J biphasic) or ibutilide (I); no flecainide/propafenone (III) → atrial fibrillation
wide complex tachycardia (QRS ≥120 ms)
Default = VT, especially with prior MI or cardiomyopathy. Haemodynamic stability does not exclude VT.
| Favours VT | Finding |
|---|---|
| AV dissociation | ventricular rate > atrial rate (dissociated P waves) — most specific |
| fusion / capture beats | intermittent normal-looking or hybrid complexes |
| negative precordial concordance | all V1–V6 predominantly negative |
| no RS complex in any precordial lead, or R-to-S nadir >100 ms | Brugada criteria |
| aVR | initial R wave, or initial r/q >40 ms (Vereckei) |
| extreme (northwest) axis | −90° to ±180° |
| lead II R-wave peak time ≥50 ms | |
| RBBB-like | V1 monophasic R, qR, or taller left “rabbit ear”; V6 R:S <1 |
| LBBB-like | V1 broad R >40 ms, slurred/notched S downstroke; V6 Q or QS |
- Other causes of wide-complex regular tachycardia: SVT with pre-existing or rate-related BBB, antidromic AVRT, paced rhythm, hyperkalaemia or Na⁺-channel blocker toxicity
- Stable WCT: DCCV or procainamide IV (IIa; CCS first line for stable VT with structural disease), amiodarone IV second line (IIb); adenosine only if no pre-excitation on a prior ECG (diagnostic for SVT with aberrancy); verapamil contraindicated
- Confirmed VT management → ventricular arrhythmias and sudden cardiac death
pre-excitation and WPW
- Accessory pathway: myocardial AV connection outside the node, conducts without nodal delay → ventricle activates early
- WPW pattern (ECG in sinus rhythm): PR <120 ms, delta wave, QRS ≥120 ms. Fusion beat — pathway starts the QRS, His-Purkinje finishes it, so the terminal QRS is normal. Prevalence 0.13–0.25%; can come and go or disappear
- WPW syndrome: pattern + AVRT, pre-excited AF/flutter or cardiac arrest. Usually presumed from a tachycardia with pre-excitation on a prior or post-conversion ECG; EPS confirms the pathway is involved
- Normal sinus ECG does not exclude a pathway: pre-excitation can be intermittent; concealed pathways conduct retrograde only → orthodromic AVRT, no delta wave
- Mimics of the pattern: MI (negative delta reads as Q wave — posteroseptal pathways give inferior “Q waves”; positive delta can hide a true infarct), BBB (WPW: abnormal start, normal end of QRS), ventricular bigeminy if alternate beats pre-excite, HCM (short PR, wide QRS; true pathways can coexist)
- Echo if structural disease suspected (HCM, Ebstein) and in athletes or safety-critical jobs
| Scenario | Management |
|---|---|
| pre-excited AF (irregular, very fast, varying wide QRS) | unstable → DCCV. Stable → procainamide or ibutilide (I, ACC/AHA), though CCS notes DCCV may be preferred as the drug evidence is thin; flecainide/propafenone with caution if no structural disease (ESC). IV amiodarone not recommended (III — enhanced pathway conduction, VF). No CCB, BB, digoxin (III; oral digoxin harmful long term too); no adenosine (contraindicated, UpToDate). Then ablate the pathway |
| pre-excited flutter (regular, wide, often >250/min) | looks like VT; manage as pre-excited AF |
| orthodromic AVRT (narrow; >90% of AVRT) | down node, up pathway; retrograde P with short RP. Vagal → adenosine (have defibrillator ready — may trigger AF) → ablation |
| antidromic AVRT (wide) | down pathway, up node; QRS matches pre-excited sinus beats. Treat as WCT: procainamide/ibutilide, DCCV; ablation. No CCB or BB (VF risk); avoid adenosine if pre-excited on resting ECG (can induce AF → arrest) |
| PJRT (narrow, long RP, incessant) | slow concealed pathway; tachycardia cardiomyopathy. Hard to suppress with drugs → ablation |
risk-stratifying the incidental pattern
About 1 in 5 asymptomatic patients develop an arrhythmia; SCD as the first event is rare and risk falls with age. The target is a pathway that can conduct AF fast enough to cause VF.
- Non-invasive (exercise test, Holter): intermittent pre-excitation or abrupt loss of pre-excitation on exercise = low-risk markers (I, ACC/AHA). Not a guarantee — about a fifth with intermittent pre-excitation still have pathway ERP <250 ms. Persistent pre-excitation does not mean high risk, it only fails to show low risk
- EPS with isoprenaline if high-risk occupation (pilot, professional driver), competitive athlete or not clearly low risk
- High risk → ablate: SPERRI or pathway ERP ≤250 ms (UpToDate uses ERP ≤240 ms), multiple pathways or inducible AVRT
- Guidelines differ on the rest: ESC favours EPS (IIa; non-invasive IIb), ACC/AHA accepts EPS or observation alone (both IIa). Sensible default: exercise test first, EPS if pre-excitation persists and ablation would be accepted; observation is reasonable in older adults
- Symptomatic = syndrome → stratification does not change the decision, refer for ablation (>90% acute success; complications 1.5–3%, AV block needing pacing 0.3–1%). Short pathway ERP, arrhythmic syncope, multiple pathways or AVRT degenerating to pre-excited AF → urgent (CCS)
sinus tachycardia
- Physiological in most → look for fever, sepsis, hypovolaemia, bleeding, PE, hypoxia, pain, anaemia, hyperthyroidism, drugs/withdrawal
- Inappropriate sinus tachycardia: resting HR >100, mean >90/24 h, no cause → exclude reversible causes first; ivabradine ± beta-blocker for symptoms (IIa, ESC); beta-blockers alone often ineffective
- POTS → postural orthostatic tachycardia syndrome
Prepared 2026-11-09. Not yet verified — check every number against the sources.
Key references
+7 more sources
- resource Di Biase L, Walsh EP, Prutkin JM. WPW pattern and syndrome: Clinical manifestations, evaluation, and risk stratification. UpToDate. Updated 14 Sep 2026.
- resource Di Biase L, Walsh EP. WPW pattern and syndrome: Management and prevention of arrhythmias. UpToDate. Updated 26 Aug 2026.
- resource Knight BP, Podrid PJ. Accessory pathways: Anatomy, electrophysiology, and epidemiology. UpToDate. Updated 30 Mar 2026.